- ongoing, recruitingHuman Pharmacology (Phase I)- Other
A double-blind, placebo-controlled, parallel-group study to evaluate the safety and efficacy of briquilimab in participants with allergic asthma.
This study is looking for adults with allergic asthma to test a new medicine called briquilimab. It aims to see if the medicine is safe and helps with asthma symptoms. Some people will get the medicine, and others a dummy treatment, without knowing which one they have.
Germany - ongoing, recruitingHuman Pharmacology (Phase I)- Bioequivalence Study
A RANDOMIZED PHASE I, DOUBLE-BLIND, PARALLEL, COMPARATIVE ASSESSMENT OF PHARMACOKINETICS, SAFETY, PHARMACODYNAMICS, AND IMMUNOGENICITY OF LT-01 (AN OMALIZUMAB BIOSIMILAR CANDIDATE [TEST]) LYOPHYLIZED POWDER FOR SUBCUTANEOUS INJECTION VERSUS EU-APPROVED XOLAIR® LYOPHYLIZED POWDER FOR SUBCUTANEOUS INJECTION (REFERENCE) IN HEALTHY SUBJETCS: CIMA STUDY.
This study is comparing a new version of a common medicine, Xolair, with the original. It's looking at how the new medicine works in the body, its safety, and if it causes an immune reaction. This is for healthy people, not those with existing conditions.
Spain - authorisedTherapeutic confirmatory (Phase III)
Intralymphatic Allergen Immunotherapy (ILIT) in grass pollen allergy: a randomized controlled trial
This study looks into a new way to treat grass pollen allergy called Intralymphatic Allergen Immunotherapy (ILIT). It's a key stage of research (Phase 3) comparing this treatment to a non-active solution to see if it can reduce hay fever symptoms like runny nose, sneezing, and itchy eyes.
Italy